With a new CEO onboard and recruitment of a mid-stage trial of its Ipsen-partnered Parkinson's disease drug just completed, Sweden's IRLAB Therapeutics AB is in a strong position to attract attention from big pharma firms which are revisiting the neuroscience space.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?